SCHEMBL4459290

SCHEMBL4459290

C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](N)C=O

nearest known ligand 0.44

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9504057 1.00 PAX8 (0.44) PAX8
SCHEMBL3899055 1.00 PAX8 (0.44) PAX8
SCHEMBL3158180 1.00 PAX8 (0.44) PAX8
SCHEMBL9504052 1.00 PAX8 (0.44) PAX8
SCHEMBL29425221 1.00 PAX8 (0.44) PAX8
SCHEMBL489573 1.00 PAX8 (0.44) PAX8
SCHEMBL476387 1.00 PAX8 (0.44) PAX8
Hydrochloric Acid SCHEMBL1722152 0.97 PAX8 (0.43) PAX8
SCHEMBL14151119 0.97 PAX8 (0.43) PAX8
SCHEMBL11403360 0.97 PAX8 (0.43) PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282806-A1 CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN JIANGNAN UNIVERSITY (CN) 2025-09-11 US claimed
EP-4243863-A2 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF Pfizer Inc. (US) 2023-09-20 EP claimed
WO-2022101745-A2 IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS AND USES THEREOF PFIZER INC. (US) 2022-05-19 WO claimed
US-10851130-B2 Chemical synthesis method of Plesiomonas shigelloides serotype O51 O-antigen oligosaccharide JIANGNAN UNIVERSITY (CN) 2020-12-01 US claimed
US-20190233459-A1 Chemical Synthesis Method of Plesiomonas Shigelloides Serotype O51 O-antigen Oligosaccharide JIANGNAN UNIVERSITY (CN) 2019-08-01 US claimed
EP-0320960-B1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1993-05-12 EP claimed
US-5145848-A AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1992-09-08 US claimed
EP-0396588-A1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1990-11-14 EP claimed
WO-1989005815-A1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1989-06-29 WO claimed
EP-0320960-A1 Amino anthracenediones-bis platinum complexes, useful as antitumoral agents BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1989-06-21 EP claimed
EP-4729073-A1 SYNTHETIC VACCINES AGAINST FRANCISELLA TULARENSIS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-04-22 EP disclosed
US-20250282810-A1 Chemical Synthesis Method and Application of V. Cholerae Serotype O100 O-Antigen Oligosaccharides JIANGNAN UNIVERSITY (CN) 2025-09-11 US disclosed
US-20250282806-A1 CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN JIANGNAN UNIVERSITY (CN) 2025-09-11 US disclosed
US-20240189797-A1 SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-06-13 US disclosed
US-20240124911-A1 ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2024-04-18 US disclosed
WO-1989005815-A1 AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) 1989-06-29 WO disclosed
EP-0320960-A1 Amino anthracenediones-bis platinum complexes, useful as antitumoral agents BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) 1989-06-21 EP disclosed
US-4831126-A Antigenic polysaccharide specific to Brucella abortus and Yersinia enterocolitica serotype 0:9 CANADIAN PATENTS & DEVELOPMENT LTD. (CA) 1989-05-16 US disclosed
EP-0015468-B1 6-DEOXYGLUCOSAMINE-PEPTIDE DERIVATIVES, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1982-12-29 EP disclosed
EP-0015468-A1 6-Deoxyglucosamine-peptide derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1980-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282810-A1 Chemical Synthesis Method and Application of V. Cholerae Serotype O100 O-Antigen Oligosaccharides DDOST, OGA, DAD1 PAX8 4329/4885
US-20240189797-A1 SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES CACYBP, MGAM, MASP2 PAX8 3552/4885
US-20250282806-A1 CHEMICAL SYNTHESIS METHOD FOR DISACCHARIDE FRAGMENT OF VIBRIO VULNIFICUS BIOTYPE 2 SEROVAR A O-ANTIGEN OGA, DDOST, FUT6 PAX8 4383/4885
US-20190233459-A1 Chemical Synthesis Method of Plesiomonas Shigelloides Serotype O51 O-antigen Oligosaccharide DDOST, OSTC, OGA PAX8 2400/4885
US-10851130-B2 Chemical synthesis method of Plesiomonas shigelloides serotype O51 O-antigen oligosaccharide DDOST, OSTC, OGA PAX8 2400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.